Recognizing that Alzheimer’s disease and related disorders (ADRD) are not unitary biologic entities we seek to define subtypes of ADRD that are therapeutically relevant so as to identify the right treatment for the right patient at the right time.
Harnessing the power of exciting new methods such as artificial intelligence, advances in the understanding of extracellular vesicles, and stem cell derived individualized models of brain disease we seek to disrupt and accelerate treatment development targeting novel therapies to distinct ADRD subtypes.
At-A-Glance: Dementia and Precision Medicine
Dementia is a big global health issue
Worldwide, over 50 million people have dementia, and there are nearly 10 million new cases every year.
Venturing into innovative leads
Researchers and clinicians at the Richman Center are collaborating to discover individualized therapeutics and diagnostics for earlier diagnosis and individualized interventions.
Leveraging big data
Collecting data from tens of thousands of patient medical records leverages the big data power analytics for leads in subtyping for diagnostics and therapeutics.
Individualized brain stem cells
A unique personalized medicine approach involves the development of hiPSC models for the characterization of biologic subtypes of AD: from blood samples, brain cell lines can be individualized.
Exo-what? Exosomes could be the key
Exosomes can even travel easily from the brain to the blood, they have the unique potential to tell us what’s going on in the brain from just a blood sample. This innovation has the potential for developing biomarkers for AD diagnosis and therapeutics.
Brain scans for early detection and more
Advancing brain imaging technology from novel to routine clinical practice for early detection and individualized treatment
Alzheimer's and Dementia Research
How can we predict individuals at-risk for cognitive decline and faster progression?
How can cutting edge quality care be made available to all persons with ADRC throughout Johns Hopkins and beyond?
How can we fast track the research from clinic to test tube and back to the clinic with blood biomarkers for subtyping and for advancing therapeutics?
How can existing brain MRI methods be refined for early detection, prognosis, or predicting response to available medications?
Can novel blood tests based on "extracellular vesicles (EVs)” be developed to learn about what’s going on in the brain so as to stage the ADRD brain disease and monitor treatment response?
Can blood derived stems cells models be used to test whether individual patients will be helped by available and emerging medication treatments?
Deeper Dive Lecture and Panel Videos
2023 Visiting Lectureship in Memory Disorders and Alzheimer’s Disease
Dina Katabi, Ph.D. presented on “AI-Enabled Markers of Parkinson's Disease and Others.” (This panel was recorded May 16, 2023)
Dementia and Precision Medicine
Dr. Constantine Lyketsos presents the current medical knowledge and research to date on memory and Alzheimer's disease and answers frequently asked questions. ("What We Are Learning About Memory and Alzheimer's" was presented in April 10, 2021.)
Patient Care for Alzheimer's Disease
The research we do directly impacts the treatment options available to our patients. Find out more about patient care for Alzheimer's Disease.
The Johns Hopkins Memory and Alzheimer's Treatment Center
The Johns Hopkins Bayview Medical Center
5300 Alpha Commons Drive, Floor 4
Baltimore, MD 21224
Dimitrios Kapogiannis, M.D. is Chief of the Human Neuroscience Unit at the National Institute of Aging and adjunct Associate Professor in the Department of Neurology at Johns Hopkins. He is a clinician-scientist, ABPN-certified in Neurology and UCNS-certified in Behavioral Neurology. His translational laboratory focuses on discovering novel biomarkers for preclinical diagnosis and therapeutic response in Alzheimer's and other neurodegenerative diseases. He has pioneered deriving Extracellular Vesicles enriched for neuronal and astrocytic origin from peripheral blood.
Using Big Data to Decode Alzheimer's Disease
Kostas Lyketsos and his team are collecting data from tens of thousands of patient medical records, looking for demographic and genetic factors that determine how the disease progresses over time.